Choi response criteria

Last revised by Joshua Yap on 23 May 2023

The solitary use of the size of the tumor during evaluation for response to chemotherapy has some pitfalls and limitations, especially for specific tumors such as gastrointestinal stromal tumor (GIST).

The Choi response criteria for GIST proposed that tumor attenuation could provide an additional measure of response to imatinib therapy. 

  • disappearance of all target lesions  

  • no new lesions 

  • ≥10% decrease tumor size on CT

  • or ≥15% decrease in tumor attenuation on CT

  • no progression of non-target lesions

  • no new lesions 

  • ≥10% increase in sum of longest diameters of lesions

  • does not meet the criteria for partial response by virtue of tumor attenuation

  • new or growing intratumoral nodules

  • new lesions

  • none of the above

  • no symptomatic deterioration that can be associated with tumor progression

  • tumor size is represented by the sum of the longest cross-sectional diameters for target lesions similarly to RECIST

  • tumor attenuation was measured in the portal venous phase in the original study 2

First proposed for metastatic renal cell cancer treated with tyrosine kinase inhibitors, the mChoi system has one major difference: both 10% decrease in size and 15% CT density are required for the diagnosis of partial response. In this setting the mChoi system was found to correlate better with time to disease progression 3.

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.